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Purpose: Since 2004, the National Cancer Screening Program of Korea has included colorectal cancer screening based on 
primary screening with the fecal occult blood test (FOBT). We report on the clinical features of colorectal cancer detected 
by the National Cancer Screening Program.
Methods: We retrospectively analyzed 577 patients who underwent elective surgery for colorectal cancer at the Seoul Na-
tional University Hospital between January 2008 and December 2009. We compared the clinical features of colorectal 
cancers detected by the National Cancer Screening Program (NCSP group) with those of the control group in terms of 
age, gender, preoperative symptom, location of the tumor, surgical technique and tumor-node-metastasis (TNM) stage.
Results: Age, gender, location of the tumor and operation types were not different between the two groups. The propor-
tion of asymptomatic patients was significantly higher in the NCSP group than it was in the control group (86.5% vs. 
20.0%; P < 0.001). The proportion of less invasive lesions (T1 or T2) was significantly higher in the NCSP group (46.3% 
vs. 27.7%; P = 0.002). The pathologic stages of the colorectal cancers in the NCSP group were I, 40.3%; II, 17.9%; III, 
40.3% and IV, 1.5% whereas in the control group, they were I, 20.8%; II, 32.9%; III, 34.9% and IV, 11.4%. The proportion 
of stage I cancer was significantly higher in the NCSP group than in the control group (40.3% vs. 20.8%; P = 0.006).
Conclusion: Our study demonstrates the FOBT in the NCSP is effective in early detection of colorectal cancer.
Keywords: FOBT; National Cancer Screening Program
with the progression of stages as the rates of stage I and stage 
IV cancer are over 90% and less than 5%, respectively. There-
fore, to reduce the mortality rate caused by colorectal cancer, 
early detection is a prerequisite [4-6]. Screening tests for early 
detection of colorectal cancer are the fecal occult blood test 
(FOBT), sigmoidoscopy, colonoscopy, and double-contrast bar-
ium enema, and a large-scale case control study using FOBT 
revealed that the mortality rate due to colorectal cancer was 
decreased by 16% in the group participating in the screening 
[7-10].
In Korea, the “Cancer Control Plan for the Next 10 Years” 
was implemented in 1996, and the second-term “Cancer Con-
trol Plan for the Next 10 Years” has been operating since 2006. 
As a plan of action, the National Cancer Screening Program 
(NCSP) has been ongoing since 1999, and the program has 
included CRC screening since 2004. For this, medical aid re-
cipients and national health insurance beneficiaries older than 
50 years take the FOBT every year, and when the result is pos-
itive, they take confirmative tests, ‘colonoscopy’ or ‘double-con-
trast barium enema’ [11] (Fig. 1). To date, however, data on 
INTRODUCTION
According to the National Cancer Registry Data reported by 
the National Cancer Information Center, colorectal cancer 
(CRC) occurs in 33 persons out of 100 thousand in Korea and 
ranks third following stomach cancer and thyroid cancer in 
terms of the incidence rate, and its incidence rate is currently 
skyrocketing [1-4]. In addition, although the five-year survival 
rate for colorectal cancer occurring from 2003 to 2007 has 
been recorded as 68.7%, the survival rate has dropped sharply 
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improved screening and survival rates due to the FOBT have 
not been reported. Therefore, this study investigated the clini-
cal characteristics of colorectal cancer detected by the FOBT 
performed in the NCSP to provide basic data on screening of 
colorectal cancer and to help to decide future directions for 
the NCSP.
METHODS
From January 2008 to December 2009, 588 patients underwent 
elective surgery for CRC at Seoul National University Hospi-
tal. We excluded 11 patients who had undergone surgery due 
to colorectal cancer or who had been diagnosed with familial 
adenomatous polyposis or hereditary non-polyposis colorectal 
cancer; the remaining 577 patients were included for analysis. 
We divided these patients into two groups; the NCSP group (n 
= 67) whose CRCs were diagnosed by using the NCSP, and the 
control group (n = 510). Demographic and clinicopathologic 
characteristics of the patients were compared between the 
groups. All statistical analyses were conducted with SPSS ver. 
17.0 (SPSS Inc., Chicago, IL, USA) for Windows, and the chi-
squared test or the independent sample t-test was utilized. A 
P-value of less than 0.05 was considered to be statistically sig-
nificant.
RESULTS
Age and gender 
The mean age of the 577 subjects was 61.6 ± 11.4 years (range, 
22 to 91 years), and the mean age of the NCSP group was signif-
icantly higher than that of the control group (64.5 ± 6.6 years 
[range, 50 to 80 years] vs. 61.2 ± 11.8 years [range, 22 to 91 years], 
respectively, P = 0.001). Of the total subjects, 356 (61.7%) and 
221 (38.3%) were males and females, respectively, for a ratio of 
1.6:1. The male-to-female ratios of the NCSP group and the 
control group were 1.9:1, with 44 (65.7%) males and 23 (34.3%) 
females, and 1.6:1, with 312 (61.2%) males and 198 (38.8%) fe-
males, respectively, and this difference was not statistically sig-
nificant (P = 0.477) (Table 1).
Preoperative symptoms
In the NCSP group, as preoperative symptoms, no symptoms, 
hematochezia, abdominal pain, change of bowel habit and dys-
pepsia were found in 58 (86.5%), 5 (7.5%), 2 (3%), 1 (1.5%) and 
1 (1.5%) cases, respectively. In the control group, hematochezia, 
changes of bowel habit, no symptoms, abdominal pain, dyspep-
sia and other symptoms were found in 183 (35.9%), 105 (20.6%), 
102 (20.0%), 85 (16.6%), 11 (2.2%) and 24 (4.7%) cases, respec-
tively. Asymptomatic patients accounted for the largest portion 
in the NCSP group while hematochezia was the main symptom 
in the control group (P < 0.001).
Location of tumors
The location of the tumor was classified as the ascending colon, 
the transverse colon, the descending colon, the sigmoid colon 
and the rectum. For the NCSP group, the tumors were located 
in the ascending colon, the transverse colon, the descending 
colon, the sigmoid colon and the rectum in 14 (20.9%), 3 (4.5%), 
1 (1.5%), 22 (32.8%) and 27 (40.3%) patients, respectively, so 
rectal cancer was observed most frequently. For the control 
group, the tumors were located in the ascending colon, the 
transverse colon, the descending colon, the sigmoid colon and 
the rectum in 70 (13.7%), 46 (9.0%), 10 (2.0%), 159 (31.2%) 
and 225 (44.1%) patients, respectively. The distributions were 
not significantly different between the two groups (P = 0.400).
Surgical treatments
In both the NCSP group and the control group, a low anterior 
resection was conducted most frequently, and the surgical treat-
ments of the two groups did not show any statistically signifi-
cant difference (P = 0.069) (Table 2). 
Histopathologic staging (TNM staging)
The rates of T1 and T2 cancers were relatively higher in the 
NCSP group (46.3%) than in the control group (27.7%), and 
the rate of stage I was also higher in the NCSP group (40.3%) 
than in the control group (20.8%) The rate of N0 cancer in the 
NCSP group was higher than that in the control group, but the 
difference was not statistically significant (Table 3).
DISCUSSION
Cancer screening for persons aged 50 and over through the  Candidate Biopsy Colonoscopy Fecal occult 
blood test
Double contrast 
barium enema
Suspected
cancer
patients
Positive (+)
Positive (+)
Fig. 1. Colorectal cancer screening procedure.
Table 1. Distribution of age and gender
NCSP group  
(n = 67)
Control group  
(n = 510)
P-value
Mean age (yr) 64.48 (±6.60) 61.19 (±11.88) <0.01
Male:Female 
   (%)
44:23  
(65.7:34.3)
312:198  
(61.2:38.8)
      0.477
NCSP, National Cancer Screening Program.Journal of The Korean Society of
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FOBT, sigmoidoscopy, colonoscopy and double-contrast bar-
ium enema is well known to be important because early detec-
tion of CRC can improve the survival and the quality of life of 
patients [12]. Out of the screening tests, the FOBT is effective, 
cheap and less invasive [13]. However, while the FOBT produces 
no complications and is cheap and simple, additional tests are 
necessary due to its low sensitivity, low positive predictive value, 
and high false positive rate [14-16]. In addition, the National 
Polyp Study in the US reported that when persons who were 
normal in colonoscopy or whose polyps were removed by using 
a polypectomy were followed for six years, the incidence rate 
of CRC was reduced by 76-90% [17]. Thus, applying colonos-
copy to all examinees can enhance detection rate; nevertheless, 
its use is limited to an additional test for persons with abnormal 
results on the FOBT because it is relatively expensive, can lead 
to serious complications, such as colonic perforation, although 
it is rarely found, provokes discomfort in examinees and requires 
skilled endoscopy specialists, who are not available in sufficient 
numbers [13, 18, 19].
In this study, while the rates of T1 and T2 cancers and stage I 
cancer were relatively higher in the NCSP group than in the 
control group, the rate of stage IV cancer in the NCSP group 
(only one patient, 1.5%) was relatively low compared to that in 
the control group. Paimela et al. [20] also reported that the rates 
of stage I and II cancers were higher in the FOBT screening 
group (52%) than in the control group (38%) in their study con-
ducted with around 100 thousand subjects from 2004 to 2006. 
That meant that CRC was detected earlier in the FOBT screen-
ing group than in the control group. This study found no signif-
icant difference in N staging between the two groups, and the 
reason is thought to be the small number of subjects. 
The patients of the NCSP group (64.5 years) were observed to 
be older than those of the control group (61.6 years). That was 
considered to be because the recipients of the National Cancer 
Screening Program were over 50 years of age and did not in-
clude young patients.
This study is limited in demonstrating the exact effects of the 
screening because of the possibility of including patients who 
had undergone CRC screening outside the tract of the NCSP 
in the control group and including symptomatic patients at the 
time of screening in the NCSP group. However, because only 
few data on the CRC screening using the FOBT performed as 
a part of the NCSP are available, the results of this study are 
meaningful as basic data. Moreover, the finding that the rate of 
detection of cancer in its early stage was significantly higher in 
the national cancer screening group than in the control group 
carries an important meaning.
The CRC patients whose tumors were detected through the 
National Cancer Screening Program by using the FOBT showed 
a higher proportion of early stage lesions, which implies that 
the current National Cancer Screening Program in Korea con-
tributes to early detection of colorectal cancer.
Table 2. Distribution of surgical treatment
NCSP group (n = 67) Control group (n = 510) P-value
Surgical treatment Right hemicolectomy (16, 23.9) Right hemicolectomy (104, 20.4) 0.069
Left hemicolectomy (1, 1.5) Left hemicolectomy (18, 3.5)
Anterior resection (22, 32.8) Anterior resection (135, 26.5)
LAR (23, 34.3) LAR (67, 32.7)
ULAR (4, 6.0) ULAR (57, 11.2)
Subtotal colectomy (1, 1.5) Others
a (29, 5.7)
Values are presented as number, %. 
LAR, low anterior resection; ULAR, ultralow anterior resection. 
aSubtotal colectomy, 6; total colectomy, 4; abdominoperineal resection, 5; Hartmann’s operation, 3; stomy, 7 (colostomy, 5; ileostomy, 2); transanal excision, 4.
Table 3. Distribution of histopathologic stage (TNM stage)
NCSP group  
(n = 67)
Control group  
(n = 510)
P-value
T-stage
   T1
   T2
   T3
   T4
   16 (23.9)
   15 (22.4)
   33 (49.2)
   3 (4.5)
  56 (11.2)
  82 (16.5)
312 (62.7)
48 (9.6)
0.002
N-stage
   N0
   N1
   N2
   Nx
   40 (59.7)
   22 (32.8)
   5 (7.5)
0 (0)
293 (57.5)
123 (24.1)
  83 (16.3)
11 (2.1)
0.077
M-stage
   M0
   M1
   66 (98.5)
   1 (1.5)
452 (88.6)
  58 (11.4) 
0.009
TNM-stage
   I
   II
   III
   IV
   27 (40.3)
   12 (17.9)
   27 (40.3)
   1 (1.5)
106 (20.8)
168 (32.9)
178 (34.9)
  58 (11.4)
0.006
Values are presented as number (%).
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